Premium
Prognostic analysis in a Chinese population with T1‐2N1 breast cancer: Did patients with 1 or 2, and 3 positive axillary lymph nodes have similar survival outcomes?
Author(s) -
Shen Honghong,
Yuan Jinyang,
Yang Yang,
Liu Xiaozhen,
Wang Li,
Feng Xiaolong,
Zhao Lin,
Niu Yun
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24062
Subject(s) - medicine , lymph , breast cancer , axillary lymph nodes , multivariate analysis , log rank test , survival analysis , univariate analysis , oncology , population , axilla , lymph node , cancer , pathology , environmental health
Background and Objectives There is a paucity of data examining whether 1–3 positive lymph nodes patients have similar survival outcomes. The present studies separately analyse survival outcomes of T1‐2N1 breast cancer patients according to the number of positive lymph nodes. Methods A total of 1,030 patients with T1‐2N1 breast cancer were available for analysis. Survival estimates were calculated using the Kaplan–Meier method, univariate, and multivariate logistic regression models Results Kaplan–Meier analysis showed progressively worse survival with the increased number of positive lymph nodes. Log‐rank test P values were 0.003 (1 vs. 2 positive LNs), <0.0001 (1 vs. 3), and 0.006 (2 vs. 3) for recurrence‐free survival (RFS). Log–rank test P values were 0.045 (1 vs. 2), <0.0001 (1 vs. 3), and 0.018 (2 vs. 3) for metastasis‐free survival (MFS). Log‐rank test P values were 0.101 (1 vs. 2), <0.0001 (1 vs. 3), and 0.005 (2 vs. 3) for overall survival (OS). Multivariate analysis showed that 3 and 2 positive lymph nodes had worse survival compared with 1 positive axillary lymph nodes. Conclusions Our study does suggest that T1‐2N1 patients showed progressively worse survival outcomes with the increased number of positive lymph nodes. J. Surg. Oncol. 2015;112:569–574 . © 2015 Wiley Periodicals, Inc.